title: Skin-derived antileukoproteinase (SKALP) is decreased in pustular forms of psoriasis. A clue to the pathogenesis of pustule formation?
abstract: Skin-derived antileukoproteinase (SKALP, also known as elafin) is an inducible epidermal serine proteinase inhibitor, that we have recently characterized at the protein and DNA levels. SKALP is a strong and specific inhibitor of PMN elastase, and is putatively involved in the regulation of cutaneous inflammatory processes. In order to investigate the role of SKALP in the control of elastase in psoriatic epidermis, we compared SKALP expression in normal skin, and in skin from patients with chronic plaque psoriasis and pustular forms of psoriasis. Epidermal scales and biopsies were collected and SKALP expression was studied at the mRNA level and at the protein level both functionally and immunochemically. In epidermal scales, we found that the levels of both free and total SKALP activity in pustular psoriasis were far lower than in plaque psoriasis. A significant number of pustular psoriasis patients showed latent SKALP activity, which represents the amount of SKALP putatively complexed to elastase. In addition, we found free elastase activity in 25% of the pustular psoriasis patients, indicating a total saturation of epidermal SKALP activity. In epidermal biopsies from pustular psoriasis patients, SKALP activity was significantly decreased compared with those from plaque psoriasis patients. Northern blot analysis did not reveal differences in epidermal mRNA levels between chronic plaque psoriasis and pustular psoriasis. We hypothesize that a reduced amount of epidermal SKALP contributes to an imbalance between elastase and its inhibitor, thereby promoting the formation of epidermal pustules. We suggest that these findings could provide a rationale for the treatment of pustular psoriasis with inhibitors of PMN-derived proteinases, as a new therapeutic modality.
authors.affiliation: Department of Dermatology, University Hospital Nijmegen, The Netherlands.
authors.forename: A L
authors.initials: AL
authors.lastname: Kuijpers
authors.forename: P L
authors.initials: PL
authors.lastname: Zeeuwen
authors.forename: G J
authors.initials: GJ
authors.lastname: de Jongh
authors.forename: P C
authors.initials: PC
authors.lastname: van de Kerkhof
authors.forename: H A
authors.initials: HA
authors.lastname: Alkemade
authors.forename: J
authors.initials: J
authors.lastname: Schalkwijk
mesh_terms: D015152:Blotting, Northern; D006801:Humans; D007150:Immunohistochemistry; D019272:Leukocyte Elastase / Q000037:antagonists & inhibitors; D009504:Neutrophils / Q000201:enzymology; D053491:Proteinase Inhibitory Proteins, Secretory; D011506:Proteins / Q000235:genetics / Q000378:metabolism*; D011565:Psoriasis / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D015842:Serine Proteinase Inhibitors / Q000235:genetics / Q000378:metabolism* / Q000627:therapeutic use; D012867:Skin / Q000378:metabolism*
chemical_list: D053491:Proteinase Inhibitory Proteins, Secretory; D011506:Proteins; D012333:RNA, Messenger; D015842:Serine Proteinase Inhibitors; D019272:Leukocyte Elastase